Back

Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiorenal-metabolic triad: the global health challenge Cardiovascular Disease in Women ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on inflammation and cardiovascular disease
Professor J. Deanfield (London, GB)
Slides Video
Presentation thumbnail
Associations between C-reactive protein levels and mortality in individuals with atherosclerotic cardiovascular disease and chronic kidney disease: results from the UK Discover database
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
Cumulative adiposity burden and cardiovascular risk trajectories: validating the 2025 clinical obesity criteria
Doctor J. Yang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Sex differences in cardio-kidney metabolic syndrome: insights from the FINE-HEART pooled analysis of >18,000 trial participants
Doctor M. Pabon (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiorenal-metabolic triad: the global health challenge
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in diabetic patients with a higher impact on women
thumbnail
Congress Presentation
Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources